4.8 Article

Enantioselective Synthesis of anti-β-Hydroxy-α-amido Esters via Transfer Hydrogenation

Journal

ORGANIC LETTERS
Volume 12, Issue 22, Pages 5274-5277

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/ol102323k

Keywords

-

Funding

  1. Knut and Alice Wallenberg Foundation
  2. Swedish Research Council
  3. Estonian Science Foundation [7808]

Ask authors/readers for more resources

The asymmetric transfer hydrogenation of alpha-amido-beta-keto esters to provide the corresponding anti-beta-hydroxy-alpha-amido esters in good to excellent yields, diastereoselectivity, and enantioselectivity is reported. The procedure is operationally simple, and delicate handling of the catalyst is not necessary.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis

S. Pauliina Turunen, Pernilla von Nandelstadh, Tiina Ohman, Erika Gucciardo, Brinton Seashore-Ludlow, Beatriz Martins, Ville Rantanen, Huini Li, Katrin Hopfner, Paivi Ostling, Markku Varjosalo, Kaisa Lehti

CELL DEATH AND DIFFERENTIATION (2019)

Article Chemistry, Multidisciplinary

Computational and Experimental Druggability Assessment of Human DNA Glycosylases

Maurice Michel, Torkild Visnes, Evert J. Homan, Brinton Seashore-Ludlow, Mattias Hedenstrom, Elisee Wiita, Karl Vallin, Cynthia B. J. Paulin, Jiaxi Zhang, Olov Wallner, Martin Scobie, Andreas Schmidt, Annika Jenmalm-Jensen, Ulrika Warpman Berglund, Thomas Helleday

ACS OMEGA (2019)

Article Cell Biology

Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors

Elaine M. Oberlick, Matthew G. Rees, Brinton Seashore-Ludlow, Francisca Vazquez, Geoffrey M. Nelson, Neekesh V. Dharia, Barbara A. Weir, Aviad Tsherniak, Mahmoud Ghandi, John M. Krill-Burger, Robin M. Meyers, Xiaofeng Wang, Phil Montgomery, David E. Root, Jake M. Bieber, Sandi Radko, Jaime H. Cheah, C. Suk-Yee Hon, Alykhan F. Shamji, Paul A. Clemons, Peter J. Park, Michael A. Dyer, Todd R. Golub, Kimberly Stegmaier, William C. Hahn, Elizabeth A. Stewart, Stuart L. Schreiber, Charles W. M. Roberts

CELL REPORTS (2019)

Meeting Abstract Hematology

High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia

Tom Erkers, Brinton Seashore-Ludlow, Nona Struyf, Francesco Marabita, Tojo James, Disha Malani, Mattias Vesterlund, Matthias Stalhl, Yudi Pawitan, Soren Lehmann, Paivi Ostling, Janne Lehtio, Olli Kallioniemi

BLOOD (2019)

Article Biochemical Research Methods

Perspective on CETSA Literature: Toward More Quantitative Data Interpretation

Brinton Seashore-Ludlow, Hanna Axelsson, Thomas Lundback

SLAS DISCOVERY (2020)

Article Biochemical Research Methods

Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC

Yan Zhou Tran, Rezan Minozada, Xiaofang Cao, Henrik J. Johansson, Rui M. Branca, Brinton Seashore-Ludlow, Lukas M. Orre

MOLECULAR & CELLULAR PROTEOMICS (2020)

Article Oncology

Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine

Thomas P. Howard, Elaine M. Oberlick, Matthew G. Rees, Taylor E. Arnoff, Minh-Tam Pham, Lisa Brenan, Mariana DoCarmo, Andrew L. Hong, Guillaume Kugener, Hsien-Chao Chou, Yiannis Drosos, Kaeli M. Mathias, Pilar Ramos, Brinton Seashore-Ludlow, Andrew O. Giacomelli, Xiaofeng Wang, Burgess B. Freeman, Kaley Blankenship, Lauren Hoffmann, Hong L. Tiv, Prafulla C. Gokhale, Cory M. Johannessen, Elizabeth A. Stewart, Stuart L. Schreiber, William C. Hahn, Charles W. M. Roberts

CLINICAL CANCER RESEARCH (2020)

Review Immunology

Nanomedicine for improvement of dendritic cell-based cancer immunotherapy

Vida Hashemi, Shohreh Farhadi, Mitra Ghasemi Chaleshtari, Brinton Seashore-Ludlow, Ali Masjedi, Mohammad Hojjat-Farsangi, Afshin Namdar, Amir Ajjoolabady, Hamed Mohammadi, Ghasem Ghalamfarsa, Farhad Jadidi-Niaragh

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

Article Hematology

The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia

Tian Mou, Yudi Pawitan, Matthias Stahl, Mattias Vesterlund, Wenjiang Deng, Rozbeh Jafari, Anna Bohlin, Albin Osterroos, Loannis Siavelis, Helena Backvall, Tom Erkers, Santeri Kiviluoto, Brinton Seashore-Ludlow, Paivi Ostling, Lukas M. Orre, Olli Kallioniemi, Soren Lehmann, Janne Lehtio, Trung Nghia Vu

Summary: This study identified 729 subtype-specific mRNAs in acute myeloid leukemia (AML) through RNA sequencing data analysis and protein validation, providing a rich collection of potential protein-based biomarkers for the AML community. An interactive resource has been made available to enable broader exploration of subtype-specific mRNA expression by the scientific community.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Article Oncology

PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair

Anna Huguet Ninou, Jemina Lehto, Dimitrios Chioureas, Hannah Stigsdotter, Korbinian Schelzig, Emma Akerlund, Greta Gudoityte, Ulrika Joneborg, Joseph Carlson, Jos Jonkers, Brinton Seashore-Ludlow, Nina Marie Susanne Gustafsson

Summary: DNA-damaging chemotherapeutics, such as platinum drugs, rely on the DNA repair capacity of cancer cells for efficacy, but cancer cells often develop resistance by altering their DNA damage response pathways. Targeting PFKFB3, which is commonly overexpressed in cancer, sensitizes cancer cells to platinum drugs and improves treatment efficacy by modulating the Fanconi anemia DNA repair pathway. Inhibition of PFKFB3 disrupts the assembly of key FA repair factors, prevents fork restart, and ultimately leads to an accumulation of DNA damage in replicating cells and fork collapse, enhancing the effectiveness of ICL-inducing cancer treatments.

CANCERS (2021)

Article Oncology

MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia

Kumar Sanjiv, Jose Manuel Calderon-Montano, Therese M. Pham, Tom Erkers, Viktoriia Tsuber, Ingrid Almlof, Andreas Hoglund, Yaser Heshmati, Brinton Seashore-Ludlow, Akhilesh Nagesh Danda, Helge Gad, Elisee Wiita, Camilla Gokturk, Azita Rasti, Stefanie Friedrich, Anders Centio, Montserrat Estruch, Thea Kristin Vatsveen, Nona Struyf, Torkild Visnes, Martin Scobie, Tobias Koolmeister, Martin Henriksson, Olov Wallner, Teresa Sandvall, Soren Lehmann, Kim Theilgaard-Monch, Mathew J. Garnett, Paivi Ostling, Julian Walfridsson, Thomas Helleday, Ulrika Warpman Berglund

Summary: TH1579 kills AML cells by inducing mitotic arrest, increasing intracellular ROS levels, and enhancing oxidative DNA damage. It shows a significant therapeutic window, is well tolerated in animals, and can be combined with standard-of-care treatments to further improve efficacy. TH1579 significantly improves survival in two different AML disease models in vivo.

CANCER RESEARCH (2021)

Article Medicine, General & Internal

Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial

Martin Jadersten, Ingrid Lilienthal, Nikolaos Tsesmetzis, Magda Lourda, Sofia Bengtzen, Anna Bohlin, Cornelia Arnroth, Tom Erkers, Brinton Seashore-Ludlow, Geraldine Giraud, Giti S. Barkhordar, Sijia Tao, Linda Fogelstrand, Leonie Saft, Paivi Ostling, Raymond F. Schinazi, Baek Kim, Torsten Schaller, Gunnar Juliusson, Stefan Deneberg, Soren Lehmann, Georgios Z. Rassidakis, Martin Hoglund, Jan-Inge Henter, Nikolas Herold

Summary: The addition of hydroxyurea to standard chemotherapy in newly diagnosed AML patients appears to be safe and effective, resulting in high rates of complete remission and reduced measurable residual disease. Targeted inhibition of SAMHD1 by hydroxyurea enhances the efficacy of cytarabine treatment.

JOURNAL OF INTERNAL MEDICINE (2022)

Article Cell Biology

Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention

Juuli Raivola, Alice Dini, Hanna Karvonen, Emilia Piki, Kari Salokas, Wilhelmiina Niininen, Laura Kaleva, Kaiyang Zhang, Mariliina Arjama, Greta Gudoityte, Brinton Seashore-Ludlow, Markku Varjosalo, Olli Kallioniemi, Sampsa Hautaniemi, Astrid Murumagi, Daniela Ungureanu

Summary: In this study, PTK7 was identified as a potential therapeutic target in ovarian cancer. It was found to modulate cell adhesion and Rho-GTPase signaling, sustain epithelial-mesenchymal transition (EMT) and cell plasticity, and mediate aberrant Wnt signaling. Targeting PTK7 exhibited synergistic activity with chemotherapeutic agents and inhibitors in ovarian cancer, providing a new approach for its treatment.

CELL DEATH & DISEASE (2022)

Article Chemistry, Analytical

A Portable, Negative-Pressure Actuated, Dynamically Tunable Microfluidic Droplet Generator

Martin Trossbach, Marta de Lucas Sanz, Brinton Seashore-Ludlow, Haakan N. Joensson

Summary: Droplet microfluidics technology has great potential in laboratory applications, but many labs struggle to fully harness its capabilities. Researchers have developed a portable droplet production setup using inexpensive commercial parts, enabling quick and easy generation of droplets of various sizes with dynamic tuning capabilities.

MICROMACHINES (2022)

Article Biochemical Research Methods

Miniaturized and multiplexed high-content screening of drug and immune sensitivity in a multichambered microwell chip

Niklas Sandstroem, Valentina Carannante, Karl Olofsson, Patrick A. Sandoz, Elisabeth L. Moussaud-Lamodiere, Brinton Seashore-Ludlow, Hanna Van Ooijen, Quentin Verron, Thomas Frisk, Madoka Takai, Martin Wiklund, Paeivi Ostling, Bjorn Onfelt

Summary: In this study, a methodology based on a multichambered microwell chip is presented, which allows for direct assessment of drug or immune cell cytotoxic efficacy. The methodology enables long-term cell culture, efficient screening, and high-quality imaging. The feasibility of this methodology is demonstrated through drug cytotoxicity screening and cellular cytotoxicity screening experiments.

CELL REPORTS METHODS (2022)

No Data Available